ArticleThe Prostate2008
Association of HPC2/ELAC2 and RNASEL non-synonymous variants with prostate cancer risk in African American familial and sporadic cases.
Article in The Prostate, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 4 syntheses or guidelines pooled it, 33 citations in OpenAlex.
- Evidence from 40 Studies that 2 Common Single-Nucleotide Polymorphisms (SNPs) of RNASEL Gene Affect Prostate Cancer Susceptibility: A Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)-Compliant Meta-Analysis.Medical science monitor : international medical journal of experimental and clinical research · 2019Pooled it
- RNASEL Asp541Glu and Arg462Gln polymorphisms in prostate cancer risk: evidences from a meta-analysis.Molecular biology reports · 2012Pooled it
- RNASEL -1385G/A polymorphism and cancer risk: a meta-analysis based on 21 case-control studies.Molecular biology reports · 2011Pooled it
- ELAC2 polymorphisms and prostate cancer risk: a meta-analysis based on 18 case-control studies.Prostate cancer and prostatic diseases · 2010Pooled it
- Genetic variation in RNASEL associated with prostate cancer risk and progression.Carcinogenesis · 2010Trial
- Association of selectedPathology oncology research : POR · 2026Article
- Carriage of Ser217Leu and Ala541Thr Variants of ELAC2 Gene and Risk Factors in Patients with Prostate Cancer in Burkina Faso.Prostate cancer · 2022Article
- Comparison of germline mutations in African American and Caucasian men with metastatic prostate cancer.The Prostate · 2021Article
- Prevalence of the Ser217Leu Variant of the ELAC2 Gene and Its Association with Prostate Cancer in Population of the Littoral Region of Cameroon.Prostate cancer · 2019Article
- Prostate Cancer Genomics: Recent Advances and the Prevailing Underrepresentation from Racial and Ethnic Minorities.International journal of molecular sciences · 2018Review
- The RNASEL -1385G/A polymorphism is associated with risk of prostate cancer in Africans.OncoTargets and therapy · 2018Review
- Association of a common genetic variant in RNASEL and prostate cancer susceptibility.Oncotarget · 2017Article
- Prognostic value of Notch receptors in postsurgical patients with hepatitis B virus-related hepatocellular carcinoma.Cancer medicine · 2017Article
- Molecular pathways in prostate cancer.Nephro-urology monthly · 2013Review
- A single nucleotide polymorphism in inflammatory gene RNASEL predicts outcome after radiation therapy for localized prostate cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2013Article
- Systems genetics in "-omics" era: current and future development.Theory in biosciences = Theorie in den Biowissenschaften · 2013Review
- Ethnical disparities of prostate cancer predisposition: genetic polymorphisms in androgen-related genes.American journal of cancer research · 2013Article
- Identification of genetic risk associated with prostate cancer using ancestry informative markers.Prostate cancer and prostatic diseases · 2012Article
- Emergent trends in the reported incidence of prostate cancer in Nigeria.Clinical epidemiology · 2012Article
- An update analysis of two polymorphisms in encoding ribonuclease L gene and prostate cancer risk: involving 13,372 cases and 11,953 controls.Genes & nutrition · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 9 institutions in 1 country.
Funding
Abstract
introductionThe RNASEL and HPC2/ELAC2 genes have been implicated in hereditary prostate cancer. Further assessment of the role of these genes in sporadic prostate cancer in African American men (AAM) is warranted.
methodsGenotyping of HPC2/ELAC2 variants (S217L, A541T), along with RNASEL variants (R462Q and E541D) was completed in 155 African American sporadic and 88 familial prostate cancer cases, and 296 healthy male controls. Logistic regression analysis was performed and odds ratios (OR) were calculated, while correcting for both age and population stratification using admixture informative markers.
resultsThe HPC2/ELAC2 217L allele was significantly associated with risk of prostate cancer when taking all cases into account (OR = 1.6; 1.0-2.6; P = 0.03). The RNASEL 541D allele was associated with a decrease in risk of prostate cancer in sporadic cases (OR = 0.4; 0.2-0.8; P = 0.01). We did not detect an association between prostate cancer risk and the RNASEL R462Q variant. Results from haplotype analyses of the two RNASEL variants revealed highly significant differences in haplotype allele frequencies between cases and controls suggesting a synergistic effect at the RNASEL locus. One haplotype in particular (462R-541D) is far more frequent in our control population and shows a strong protective effect against prostate cancer (OR = 0.47, P = 8.1 x 10(-9)).
conclusionsThese results suggest that HPC2/ELAC2 and RNASEL may play a role, however minor, in prostate cancer risk among AAM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.